

February 28, 2019  
Symbio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

**Notice concerning Nominations for the Board of Directors /  
the Audit & Supervisory Board / and Substitute Member for the Audit & Supervisory Board**

Symbio Pharmaceuticals Limited (“the Company”) today announced that proposals for the election of six (6) directors, one (3) Audit & Supervisory Board member, and one (1) substitute member for the Audit & Supervisory Board will be submitted at the 14th Ordinary General Meeting of Shareholders scheduled for March 28, 2019 (the “14th Shareholders Meeting”). The Company’s Board of Directors today approved the submission of the proposals to the shareholders at the 14th Shareholders Meeting.

1. Nomination of Candidates for the Board of Directors

(1) Nomination of Candidates for the Board of Directors (Re-nomination)

Mr. Fuminori Yoshida, Representative Director, President & CEO

Mr. Kazuo Asakawa, Representative Director, Executive Vice President & CCO

Mr. Shigetoshi Matsumoto, Representative Director (Outside)

(2) Nomination of Candidates for the Board of Directors (Newly nominated)

Mr. Kenji Murata, Corporate Officer & CFO

Profile of the Candidate

Date of Birth	July 19, 1968	
Career Summary	April, 1991	Sumitomo Life Insurance Company.
	October, 2004	Strategic Sourcing Manager of Novartis Pharma K.K.
	July, 2007	Head of Oncology Planning & Control of Novartis Pharma K.K.
	January, 2014	Country CFO of Novartis Animal Health K.K.
	January, 2015	Country CFO of Elanco Japan (acquisition of Eli Lilly)
	December, 2016	Head of Finance and Accounting of Symbio Pharmaceuticals Limited
	March, 2018	Corporate Officer, CFO of Symbio Pharmaceuticals Limited

Mr. Dr. Bruce David Cheson

Profile of the Candidate

Date of Birth	April 06, 1946	
Career	July, 1971	Internship of Internal Medicine, University of Virginia Hospital

Summary	July, 1973	Senior Assistant Resident of Internal Medicine, University of Virginia Hospital
	July, 1974	Clinical and Research Fellow of Hematology, New England Medical Center Hospital
	July, 1977	Assistant Professor of Medicine, Hematology/Oncology of University of Utah School, University of Utah Hospital
	October, 1984	Senior Investigator and Head of Medicine Section, National Cancer Institute, Cancer Therapy Evaluation Program
	June, 2001	Scientific Advisory Board, Lymphoma Research Foundation (current)
	July, 2002	Deputy Chief, Hematology-Oncology, Head of Hematology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center
	March, 2013	Hematology-Oncology Fellowship Program Director GUH
	August, 2016	External board of director, Morphosys (current)
	December, 2018	Frank M. Ewing Foundation Chair in Hematology-Oncology (current)

Mr. Rockford Douglas Norby

Profile of the Candidate

Date of Birth	June 28, 1935	
Career Summary	September, 1979	Senior Vice President and Chief Financial Officer of Syntex Corporation
	February, 1985	President and Chief Operating Officer of Lucasfilm, Ltd.
	December, 1996	Board of director, Executive Vice President of LSI Logic Corporation
	September, 1999	Director and Chair of the Audit Committee, Lead Independent Director of Alexion
	March, 2010	Chairman of the Board of MagnaChip Semiconductor
	November, 2017	Board of Director of Krystal Biotech, Inc. (current)

2. Nomination of Candidate for the Audit & Supervisory Board

(1) Nomination of Candidates for the Audit & Supervisory Board (Re-nomination)

Mr. Kiyoshi Watanabe, the Audit & Supervisory Board (Outside)

Mr. Kesao Endo, the Audit & Supervisory Board (Outside)

(2) Nomination of Candidates for the Audit & Supervisory Board (Outside) (Newly nominated)

Mr. Eiji Ebinuma

Profile of the Candidate

Date of Birth	July 3,1957	
Career Summary	April, 1980	The Industrial Bank of Japan, Ltd (Currently Mizuho Bank Ltd.)
	April, 2002	Deputy General Manager of Personnel Dept., Head of Planning team , Mizuho Bank, Ltd.
	April, 2003	Head of President Office and Planning dept., Olympic Group Corporation
	December, 2008	Attorney-At-Law, Toranomom Sougoh Law Firm
	January, 2013	Attorney-At-Law, Partner, Tanabe&Partners
	June, 2014	Outside Director, MIRAIT Holdings Corporation (current)
	June, 2016	Outside Director, Rakuten Bank, Ltd.(current)

3. Nomination of Candidates as a Substitute Member of the Audit & Supervisory Board

- (1) Nomination of Candidates as a Substitute Member of the Audit & Supervisory Board (Outside)  
(Re-nomination)

Mr. Mr. Takashi Watanabe as a Substitute Member of the Audit & Supervisory Board (Outside)

4. Members of the Board of Directors and the Audit & Supervisory Board who will resign

- (1) Board of Directors

Dr. George Morstyn, Director (Outside)

Dr. Milton Grannatt, Director (Outside)

Mr. Robin Campbell, Director (Outside)

- (2) Audit & Supervisory Board Member

Mr. Saneaki Ichijo (Outside)

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125